VSVana Sypsa

Vana Sypsa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vana Sypsa has a total of 347 co-authors. Here are the top co-authors by number of shared publications:

  • Angelos Hatzakis

    Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

    18 shared publications
  • Sotirios Roussos

    Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece

    18 shared publications
  • Dimitrios Paraskevis

    Department of Hygiene Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Greece

    15 shared publications
  • Angelos Hatzakis

    Dept. of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 11527, Greece; Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, Athens, Greece

    13 shared publications
  • Mina Psichogiou

    1st Department of Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece

    11 shared publications
  • George V. Papatheodoridis

    1(st) Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece

    9 shared publications

Latest Publications

  • Open Access

    Increasing HCV Diagnosis and Treatment Uptake Among Community‐Recruited People Who Inject Drugs in Athens, Greece, During the Transition to Unrestricted Access to Direct‐Acting Antivirals

    by Sotirios Roussos, Georgios Papatheodoridis, Theodoros Angelopoulos, Evangelos Cholongitas, Nikolaos Papadopoulos, Spyridon Savvanis, Athina Chounta, Fani Pliarchopoulou, Panagiota Ioannidou, Melanie Deutsch, et al.

    Eliminating hepatitis C requires focusing efforts on people who inject drugs (PWID). The ARISTOTLE HCV‐HIV program aimed to increase HCV and HIV diagnosis and linkage to care among PWID, particularly those currently injecting and not linked to opioid agonist treatment (OAT). This study evaluated HCV diagnosis and linkage to direct‐acting antiviral (DAA) treatment before and after removal of fibrosis‐based treatment restrictions. ARISTOTLE HCV‐HIV (April 2018–February 2020) was conducted in a community setting at a fixed site in central Athens. Two respondent‐driven sampling rounds recruited PWID. Single‐visit procedures included interviews, blood collection, and liver fibrosis assessment. Reflex HCV‐RNA/HCV genotype testing was performed. Participants were linked to collaborating clinicians for DAA treatment. We estimated program reach by exploratory two‐source capture–recapture and constructed HCV care cascades. DAA initiation was assessed from the first visit documenting HCV monoinfection through 180 days after the last such visit. Among 1634 unique participants, 75.0% reported past‐30‐day injecting (exploratory model‐based reach among this population in Athens: 73.2%), 22.9% were currently receiving OAT, and 26.8% were currently homeless. Anti‐HCV prevalence was 76.9% (95% CI: 74.8–78.9), 83.3% (95% CI: 80.8–85.6) of anti‐HCV–positive individuals had viremia. Of 587 monoinfected individuals eligible for treatment, 43.4% initiated DAA. Lifting fibrosis restrictions boosted DAA utilization by 19.2 treatment courses/100 anti‐HCV–positive PWID. DAA access increased substantially after lifting liver fibrosis restrictions. Peer‐driven, community‐based interventions can achieve substantial program reach among underserved PWID and contribute to HCV elimination.

  • Open Access

    Time to sustained control of the effective reproduction number as a failure-time estimand: a county-level analysis of the first SARS-CoV-2 wave in the United States

    by Athanasios Kakasis, Marianna Panagiotidou, Nikolaos Demiris, Evangelia Samoli, Vana Sypsa

    Subnational analyses of emerging pathogen transmission typically model the reproduction number (R t ) as a continuous outcome and estimate average associations with its level. Operationally, however, response planning depends on a different quantity: which jurisdictions bring transmission below the epidemic threshold (R t t . Cases accumulate faster where transmission is faster, so entry time depends on the outcome process itself and on factors that drive early spread. We account for this outcome-dependent observability using a mixed-effects Cox proportional hazards model with calendar-time left truncation and state-level Gaussian frailties, applied to 2,956 US counties observed between January 22 and July 15, 2020. The primary event was defined as the first three-day sustained reduction of mean R t below one. Control was rare (171 counties, 5.8%). Each standard-deviation increase in log population density was associated with a lower rate of control (hazard ratio 0.54; 95% confidence interval 0.44–0.67) and higher policy stringency with a faster rate (HR 1.50; CI 1.09–2.05). Evaluating jurisdictions by their rate of reaching an operational target - rather than by average transmission level - provides a clearer, decision-relevant metric for prospective allocation decisions and public health interventions.

  • Open Access

    Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort

    by George V. Papatheodoridis, George Dalekos, Ramazan Idilman, Vana Sypsa, Maria Buti, Jose Luis Calleja, Spilios Manolakopoulos, Edo Dongelmans, Marta Borghi, Margarita Papatheodoridi, et al.


  • Open Access

    Rapid ART Initiation with BIC/FTC/TAF in People Who Inject Drugs in Greece: Results from a Pilot Single-Arm Study of an Integrated Care Model

    by Sotirios Roussos, Konstantinos Protopapas, Elpida Mastrogianni, Charisis Totsikas, Charalampos D. Moschopoulos, Stylianos Bourmpoutelis, Panagiota Resta, Kassandra Procter, Evangelos Kokolesis, Anastasia Antoniadou, et al.

    People who inject drugs (PWIDs) remain underserved in HIV care. Evidence on rapid antiretroviral therapy (ART) for PWID is limited. We evaluated feasibility, effectiveness, safety, and patient-reported outcomes (PROs) for rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) supported by a peer navigation in Greece. This is a single-arm, multicenter pilot study including PWIDs (≥18 years) newly diagnosed or relinking after >3 months off ART. Participants started BIC/FTC/TAF on the same day or within 7 days and received peer navigation for 48 weeks. Co-primary endpoints were Week-24 virologic suppression (HIV-1 RNA < 50 copies/mL; FDA Snapshot) and grade 3–4 adverse events (AEs). Secondary endpoints included complete-case suppression at Weeks 24/48, CD4 recovery, retention, and PROs. Outcomes were compared with historical controls from the same centers. Thirty-seven participants were enrolled (83.8% male; median age 33.3 years). Median time to ART was 0 days (vs 78 in controls, p < 0.001). Retention was 67.6% at Week 24 and 54.1% at Week 48. In the primary (FDA Snapshot) analysis, suppression was 62.2% and 54.1% at Weeks 24 and 48; in complete-case analyses, results were 92.0% and 100%, respectively. Mean CD4 count increased by 208 cells/μL (95% CI 141–275) at Week 48. Quality of life improved and symptom burden decreased. No grade 3–4 AEs occurred. Rapid BIC/FTC/TAF with peer navigation eliminated delays to ART and achieved favorable virologic, immunologic, and PROs among those retained, with good tolerability. Despite retention challenges, this model appears feasible for PWID and may help close HIV care gaps toward UNAIDS 95–95–95 targets.

  • Causes of death among people living in prison in Greece: A 9-year retrospective study (2010–2018) at the national prison hospital

    by Sofia Boundi, Sotirios Roussos, Vana Sypsa

    People living in prisons have higher mortality rates compared to the general population. We undertook a retrospective analysis of deaths recorded between 2010 and 2018 at the sole prison hospital in Greece (Korydallos Prison Special Health Centre for men) to assess the causes of death overall and by type of offence (drug-related or other), sociodemographic characteristics by cause of death, and mortality trends over time. Permission to access forensic reports and criminal files was obtained from the relevant authorities. Deaths were categorized as either non-natural (drug overdose, suicide, and homicide) or natural (cardiovascular disease, cancer, and others). Between 2010 and 2018, 236 deaths were reported; 80.9% were natural deaths, and 19.1% were non-natural deaths. The primary causes of death were circulatory disease (34.7%), cancer (17.8%), suicide (10.2%), respiratory disease (8.9%), and overdose (6.4%). Suicide and overdose accounted for 53.3% and 33.3% of non-natural deaths, respectively. The mean (SD) age at death was 52.4 (16.2) years, with individuals experiencing non-natural deaths being significantly younger than those experiencing natural deaths [39.1 (10.5) vs. 55.5 (15.7), p < 0.001]. Among individuals incarcerated for drug-related offences, 23.8% died from non-natural causes, with drug overdose accounting for 60% of non-natural deaths. A significant peak in mortality was observed in 2013. This study emphasizes the need to closely monitor mortality rates, including drug-related fatalities, to implement suicide prevention training as well as measures to prevent deaths by overdose, including comprehensive harm reduction strategies, overdose education, and naloxone training.

  • Open Access

    Social Contact Patterns and Age Mixing before and during COVID-19 Pandemic, Greece, January 2020–October 2021

    by Vasiliki Engeli, Sotirios Roussos, Nikolaos Demiris, Angelos Hatzakis, Vana Sypsa

    We collected social contact data in Greece to measure contact patterns before (January 2020) and during the COVID-19 pandemic (March 2020-October 2021) and assess the effects of social distancing over time. During lockdowns, mean daily contacts decreased to 2.8-5.9 (mean prepandemic 20.4). Persons >65 years of age retained the fewest contacts during the pandemic (2.1-4.1). Compared with the first lockdown (March-April 2020), the second lockdown (November-December 2020) and third lockdown (April 2021) showed higher numbers of contacts (incidence rate ratio 1.50 [95% CI 1.27-1.76] in second lockdown and 2.19 [95% CI 1.86-2.58] in third lockdown). In 2021, an increase in contacts was apparent, which persisted during the April 2021 lockdown among persons 18-64 years of age. Our study provides evidence of the waning observance of physical distancing. Effective risk communication alongside targeted social distancing could offer alternatives to repeated lockdowns.


  • Open Access

    Missed opportunities for early HIV diagnosis in Greece: The MORFEAS study, 2019 to 2021

    by Sotirios Roussos, Nikos Pantazis, Konstantinos Protopapas, Anastasia Antoniadou, Antonios Papadopoulos, Giota Lourida, Vasileios Papastamopoulos, Maria Chini, Konstantinos Alexakis, Emmanouil Barbounakis, et al.

    Background: Late HIV diagnosis (CD4+ T-cell count < 350 cells/μL, or with an AIDS-defining event) remains a persistent challenge in Greece, indicating potential missed opportunities (MOs) for earlier testing. Aim: To determine the frequency of HIV indicator conditions (ICs) preceding diagnosis and to quantify MOs for earlier testing at a nationwide level in Greece. Methods: This multicentre retrospective study analysed data on 823 antiretroviral therapy-naive adults (≥ 18 years) diagnosed with HIV during 2019–21. Medical records were reviewed to identify pre-diagnosis healthcare contacts (HCCs) and ICs justifying HIV testing. Univariable and multivariable logistic regression identified factors associated with ≥ 1 MO. A Bayesian model estimated the time from seroconversion to diagnosis. Results: Among 517 participants with HCC data, 249 had ≥ 1 HCC. Of these, 59.0% (147/249) were late presenters. These cases had 365 HCCs, and 191 (52.3%) were MOs for testing. The most common ICs were sexually transmitted infections (39.8%; 76/191) and fever (11.0%; 21/191). Non-Greek origin was associated with lower odds of experiencing ≥ 1 MO (adjusted odds ratio: 0.48; 95% CI: 0.22─1.02), while higher education increased odds of MOs for early HIV diagnosis. Median time from seroconversion to diagnosis was 3.2 years for the full sample and 3.7 years for those with HCC, with about half of the latter reporting MOs post-estimated seroconversion. Recognising MOs would have potentially spared approximately 1 year of delay in diagnosis. Conclusion: MOs for earlier HIV diagnosis were prevalent in Greece. Leveraging IC-guided testing and addressing barriers could support earlier diagnosis and treatment, limiting adverse health outcomes and preventing transmission.


  • Open Access

    Incidence of primary hepatitis C infection among people who inject drugs during 2012–2020 in Athens, Greece

    by Sotirios Roussos, Christos Bagos, Theodoros Angelopoulos, Savvas Chaikalis, Evangelos Cholongitas, Spyridon Savvanis, Nikolaos Papadopoulos, Andreas Kapatais, Athina Chounta, Panagiota Ioannidou, et al.

    One of the World Health Organization's targets for the 2030 viral hepatitis elimination strategy is to reduce new hepatitis C (HCV) infections. In Athens, Greece, people who inject drugs (PWID) have a high HCV prevalence, with increasing trends since the 2000s. This analysis aims to assess primary HCV incidence among PWID during 2012–2020. Two community‐based interventions were implemented in 2012–2013 and 2018–2020 with repeated sero‐behavioural surveys in each period. Participants enrolled in multiple surveys were identified through linkage. To assess trends in HCV transmission, three indicators were estimated: (i) anti‐HCV prevalence among ‘new’ injectors (those injecting ≤2 years), (ii) indirect HCV incidence among ‘new’ injectors, assuming infection occurred at the midpoint between initiating injection and the first positive test, and (iii) HCV incidence from repeat participants. There were 431 and 125 ‘new’ injectors, respectively, in 2012–2013 and 2018–2020. Αnti‐HCV prevalence [95% CI] declined from 53.6% [48.8%, 58.3%] in 2012–2013 to 40.0% [31.3, 49.1%] in 2018–2020 (25.4% reduction, p = .007). The indirect estimate [95% CI] of HCV incidence among ‘new’ injectors decreased from 56.1 [49.3, 63.8] to 39.0/100 person‐years (PYs) [29.6, 51.5] (30.5% reduction, p = .020). HCV incidence [95% CI] based on seroconversions in repeat participants (16/63 in 2012–2013 and 9/55 in 2018–2020) declined from 64.6 [39.6105.4] to 13.8/100 PYs [7.2, 26.5], respectively (78.6% reduction, p < .001). Primary HCV incidence remains high among PWID in Athens. Consistent implementation of combined interventions, including high‐coverage harm reduction programs and initiatives tailored to increase access to HCV treatment, is essential to sustain the declining trends documented during 2012–2020.